Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8868237 | 0.98 | TBXAS1 (0.55) | TBXAS1CYP2C19CYP2D6SRCAMPD2 | |
| SCHEMBL2364634 | 0.96 | CYP2C19 (0.50) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| SCHEMBL27456894 | 0.91 | TBXAS1 (0.44) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| SCHEMBL14360139 | 0.90 | TBXAS1 (0.60) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| SCHEMBL909284 | 0.88 | CYP2C19 (0.53) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| Ammonia Solution, Strong SCHEMBL28562956 | 0.88 | TBXAS1 (0.59) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| Ammonia Solution, Strong SCHEMBL28556745 | 0.88 | TBXAS1 (0.59) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| SCHEMBL7830236 | 0.88 | CYP2C19 (0.53) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| Hydrochloric Acid SCHEMBL908468 | 0.86 | CYP2C19 (0.52) | TBXAS1CYP2C19CYP2D6SRCPOLB | |
| SCHEMBL961245 | 0.85 | POLB (0.50) | TBXAS1CYP2C19CYP2D6POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941147-B2 | Bicyclic heteroaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102356081-A | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2012-02-15 | — | — | CN | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HUWE1, APP, PSEN1 | TBXAS1 363/4885CYP2C19 2884/4885CYP2D6 3086/4885 |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HUWE1, APP, HTT | TBXAS1 1410/4885CYP2C19 3283/4885CYP2D6 1846/4885 |
| US-10941147-B2 | Bicyclic heteroaryl derivatives | HUWE1, APP, HTT | TBXAS1 1410/4885CYP2C19 3283/4885CYP2D6 1846/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | TBXAS1 1509/4885CYP2C19 2868/4885CYP2D6 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.